

Bilateral Contacts Policy

IGEA Pharma NV is committed to maintaining a good relationship and dialogue with its shareholders. Conversations with shareholders, both in general meetings and on a bilateral basis, form an integral part of this dialogue.

IGEA Pharma NV will take into consideration all requests from shareholders to enter into a conversation. IGEA Pharma NV will agree to such requests for those situations where the Management Board and/or the Supervisory Board deem this in IGEA Pharma NV's interest.

The initiative to enter into a conversation with a shareholder can also be taken by IGEA Pharma NV.

In order to assess whether a conversation with shareholders could be in IGEA Pharma NV's interest, IGEA Pharma NV may request shareholders to provide certain (written) information.

Any explanations and discussions shall be based on information that is already in the public domain.

Contacts with investors and sell-side analysts will at all times be conducted in compliance with applicable rules and regulations, in particular, those concerning selective disclosure, price sensitive information and equal treatment.

Bilateral meetings with (potential) shareholders will not be held during 'closed periods', which normally run for a period of one-month (thirty (30) calendar days) immediately prior to the first publication of the annual, half-year results of IGEA Pharma NV and for a period of 21 calendar days immediately prior to the announcement of payment of an interim or other dividend by IGEA Pharma NV.

IGEA Pharma NV's policy is that, where possible, at each conversation with shareholders at least two Company representatives shall be present. In most cases, the CEO and/or the CFO will speak with shareholders.

A request by a shareholder to meet with one or more members of the Supervisory Board (whether or not in the presence of members of the Management Board), shall be assessed by the Supervisory Board in consultation with the CEO.

The Management Board is authorized to adopt and amend this policy, subject to the approval of the Supervisory Board. The Management Board, with the approval of the chairperson of the Supervisory Board, and the Supervisory Board retain their right to deviate from this policy.